People with psoriasis might receive unexpected benefits from cutting-edge weight loss drugs like Ozempic and Zepbound, German researchers reported at a conference in Paris. File Photo by Ida Marie Odgaard/EPA
People with psoriasis might receive unexpected benefits from cutting-edge weight loss drugs like Ozempic and Zepbound, a new study says.
Psoriasis patients taking GLP-1 drugs had a 78% lower risk of premature death and a 44% lower risk of heart attack, stroke or other heart-related health crisis, researchers reported Thursday at a meeting of the European Academy of Dermatology and Venereology in Paris.
These patients also had a 65% lower risk of alcohol abuse and nearly 50% lower risk of substance abuse, researchers said.
"Our findings suggest that GLP-1 receptor agonists may offer benefits beyond their effects on weight and glucose control, particularly for cardiovascular and psychiatric outcomes in people with psoriasis," lead author Ralf Ludwig, a professor at the Lubeck Institute of Experimental Dermatology in Germany, said in a news release.
